
PaySign Inc (PAYS) Stock Forecast & Price Target
PaySign Inc (PAYS) Analyst Ratings
Bulls say
PaySign Inc. is projected to experience a robust revenue growth of 26% year-over-year in 2025, reaching a total of $73.4 million, alongside a significant increase in adjusted EBITDA, which is expected to rise by 72% year-over-year to $16.6 million. Additionally, the company anticipates an expansion of adjusted EBITDA margins, forecasted to grow by 570 to 650 basis points year-over-year, reaching between 22.2% and 23.0%, primarily driven by higher margins in its pharmaceutical segment. Furthermore, in the first quarter, PaySign reported an impressive 193% year-over-year increase in adjusted EBITDA to $5.0 million, surpassing forecasts by $0.6 million, indicating strong operational performance.
Bears say
PaySign Inc. experienced a significant contraction in its Plasma Donor Compensation segment, with revenue declining by 9% year-over-year to $9.4 million, falling short of forecasts by 5%. This decline is attributed to an oversupply of plasma in the U.S., driven by new extraction techniques that have reduced the average donor compensation per unit. Furthermore, historical performance reflects a concerning trend, as total revenue in 2020 plummeted by 30% year-over-year to $24 million, alongside a negative adjusted EBITDA of $2.8 million, down from a positive $10.1 million in 2019.
This aggregate rating is based on analysts' research of PaySign Inc and is not a guaranteed prediction by Public.com or investment advice.
PaySign Inc (PAYS) Analyst Forecast & Price Prediction
Start investing in PaySign Inc (PAYS)
Order type
Buy in
Order amount
Est. shares
0 shares